4-methylpyrazole and Acetaminophen Metabolism
- Registration Number
- NCT03878693
- Lead Sponsor
- University of Arizona
- Brief Summary
Oxidative metabolism of APAP will be studied with and without 4-MP.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
- Healthy
- No APAP use in previous 2 weeks
- No ingestion of alcohol or drugs that affect CYP 2E1 over previous 5 days
- No allergy to APAP or fomepizole
- BMI < 29
Exclusion Criteria
- Pregnant or lactating
- History of alcohol abuse
- Allergy to APAP or fomepizole
- Screening LFTs above normal range
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description B APAP Oral APAP. A Fomepizole Oral APAP and IV Fomepizole. A APAP Oral APAP and IV Fomepizole.
- Primary Outcome Measures
Name Time Method Oxidative metabolism of APAP 24 hours Measurement of oxidized metabolites of APAP
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the mechanism of 4-methylpyrazole in inhibiting acetaminophen metabolism pathways?
How does fomepizole compare to other alcohol dehydrogenase inhibitors in APAP toxicity management?
What are the key biomarkers for predicting APAP metabolism in healthy volunteers with 4-MP?
What adverse events are associated with 4-methylpyrazole in early-phase drug trials?
Are there combination therapies involving 4-methylpyrazole and APAP for improved metabolic outcomes?
Trial Locations
- Locations (1)
BUMCP - Department of Medical Toxicology
🇺🇸Phoenix, Arizona, United States
BUMCP - Department of Medical Toxicology🇺🇸Phoenix, Arizona, United States